Skip to main content

Table 1 Characteristics of the included studies

From: The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

Study Year Location Number (age)a Drug (dosage) Durationb
UDCA Monotherapy
Laurin et al. [24] 1996 USA 25 (46 y) vs. 16 (50 y) UDCA (13-15 mg/kg/d)/Clofibrate (1 g twice daily) 12 m
Lindor et al. [25] 2004 USA/Canada 80 (45.4 y) vs. 86 (48.5 y) UDCA (13-15 mg/kg/d)/placebo (tablet) 24 m
Dufour et al. [20] 2006 Switzerland 18 (47 y) vs. 15 (45 y) UDCA (13-15 mg/kg/d)/placebo (tablet) 24 m
Kiyici et al. [26] 2003 Turkey 17 (43.7 y) vs. 27 (50.2 y) UDCA (13-15 mg/kg/d)/Atorvastatin (10 mg/d) 6 m
Hong Qian, et al. [32] 2007 China 26 vs. 26 UDCA (15-20 mg/kg/d)/polyene phosphatidylcholine (1368 mg/d) 6 m
Zhu Hong-juan [27] 2010 China 30 (42.5 y) vs. 30 (43.6 y) UDCA (750 mg/d)/placebo (tablet) 2 m
Ratziu et al. [28] 2011 France 55 (49.8 y) vs. 61 (49.6 y) UDCA (28-35 mg/kg/d)/placebo (tablet) 12 m
Leuschner et al. [29] 2010 Germany 94 (41.5 y) vs. 91 (45.0 y) UDCA (23-28 mg/kg/d)/placebo (tablet) 18 m
UDCA combined with other drugs
Dufour et al. [20] 2006 Switzerland 15 (46 y) vs. 15 (45 y) UDCA (13-15 mg/kg/d) + Vitamin E (400 IU/d)/placebo (tablet) 24 m
Zhuang Xue-shan [30] 2009 China 40 vs. 42 UDCA (750 mg/d) + polyene phosphatidylcholin (1368 mg/d)/polyene phosphatidylcholine (1368 mg/d) 6 m
Sun Yan [31] 2007 China 76 vs. 61 UDCA (300 mg/d) + Silymarin (231 mg/d)/Silymarin (231 mg/d) 3 m
Lv Hong [33] 2005 China 40 vs. 40 UDCA (450 mg/d) + glycyrrhizin (450 mg/d)/placebo (tablet) 2 m
Liu Zhi-ye [34] 2006 China 96 (42.5 y) vs. 54 (47.6 y) UDCA (900 mg/d) + Tiopronin (600 mg/d)/ UDCA (900 mg/d) 3 m
  1. anumber and mean age were displayed as treatment: control group; bduration reported in months; blue indicates a higher dose of UDCA.